Copperleaf Capital LLC Has $737,000 Stock Holdings in Cencora, Inc. $COR

Copperleaf Capital LLC decreased its holdings in Cencora, Inc. (NYSE:COR) by 43.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,357 shares of the company’s stock after selling 1,836 shares during the period. Copperleaf Capital LLC’s holdings in Cencora were worth $737,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of COR. Security Financial Services INC. grew its position in Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares during the last quarter. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Hemington Wealth Management boosted its stake in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after purchasing an additional 35 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after purchasing an additional 36 shares during the last quarter. Finally, Quadcap Wealth Management LLC increased its position in Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Up 1.5%

Shares of NYSE:COR opened at $355.20 on Friday. The firm has a market cap of $68.90 billion, a P/E ratio of 44.68, a P/E/G ratio of 1.66 and a beta of 0.66. Cencora, Inc. has a 12-month low of $236.68 and a 12-month high of $377.54. The business has a fifty day simple moving average of $349.75 and a 200 day simple moving average of $319.56. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the previous year, the company posted $3.34 EPS. The business’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

Insider Activity

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 20,317 shares of company stock valued at $7,009,260 in the last ninety days. 10.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on COR shares. Evercore ISI set a $400.00 target price on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. UBS Group increased their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Mizuho boosted their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Cencora in a research report on Monday, December 29th. Finally, Barclays started coverage on Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $381.42.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.